HYIT Pharmaceutical 2016: Nutraceutical, UDCA,Trastuzumab,Bulk Drugs,Bio banking & Artificial Tears

HALF YEARLY INDUSTRY TRACKER (HYIT) is a unique biannual periodical from SKBKS covering a diverse range of 20 industries. Further, each issue of HYIT concentrates on a specific industry and its six segments, providing useful and valuable market insights both at national and international level.

HYIT –Vol. 1 of Pharmaceutical industry covers the following industry segments:

  • Nutraceutical
  •  UDCA
  •  Trastuzumab
  •  API or Bulk Drugs
  •  Bio banking
  •  Artificial Tears

HYIT delves into the Global and Indian market scenario, strategically assessing market growth potential. It provides content and data focusing on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. The periodical helps gain competitive intelligence about the market in a quick and cost effective way. It helps in empowering your branding and marketing strategies.

The publication provides a basic overview of the industry which includes definition, classification, benefits, applications etc.

It focuses on Global and Indian market providing information such as market size, structure and share, market trends, growth drivers. The report also states the production/consumption details, export- import details, supply and demand, developments, investments and industry specific regulatory environment.

With necessary tables and figures the publication puts across the   important statistics on the past, current and future status of the industries.

Table of Content

  1. Market Overview
    • Introduction
    • History/ Evolution of the product
    • Uses/Applications
  1. Market Dynamics
    • Market Size & growth
    • Share of organized and unorganized players
    • Demand and Supply of the product
    • Key Drivers
    • Restraints
    • Opportunities
    • Challenges
  1. Global Market Scenario
    • Analysis of current market Scenario globally
    • Global Market by Demography
    • Key Market players (Share)
  1. Indian Market Scenario
    • Analysis of current market Scenario
    • Key Market players/ Specific product name or brand
    • Market share
  1. Exports/ Imports
    • Major Countries Export/ Import
    • Quantity Export /Import (over five years)
  1. Competitive Landscape
    • Porters five force Model
    • Analysis of current and upcoming product categories of high growth rate within the industry.
    • Analysis of technology development and
    • Competitive analysis of key market
  1. Government Policy & Regulations for
  1. Analyst view

Note: Figure and Tables provided wherever necessary

Reasons to buy

  • Stakeholders can keep track and identify market trends, opportunities, growth drivers, and challenges behind the market change.
  • Get acquainted with the recent developments, innovations and technology updates.
  • Assess the market performance and build your investment strategy and marketing strategy.
  • Build up your content in your presentations and add weight to pitches by the data presented.






During FY16, the Indian pharmaceutical industry has performed significantly well. The industry’s top-line (top fifteen companies according to market cap) improved by 14.45% to Rs861.22bn in FY16 as compared to Rs752.50bn in FY15, backed by a healthy growth in the companies’ export revenues, especially from the US market.  Operating profit increased over 32% to Rs 258.93bn in FY16 as compared to Rs195.91bn in previous year, led by healthy growth in net sales. Profit after tax (PAT) (top fifteen companies according to market cap) grew 41% to Rs161.27bn as compared to Rs114bn in FY15 supported by healthy sales growth combined with an over 30% increase in operating profits. Among the top performers were Cipla posted a net profit of Rs117.35bn, followed by Lupin Rs 108.10bn and Dr Reddy’s Rs101.51bn.

The Indian pharmaceutical industry, the largest provider of cost-effective generic medicines to the developed world leads the  pharmaceutical exports to the world.  India has probably the largest number of USFDA approved pharmaceutical manufacturing facilities. The country is also the largest global provider of generic drugs, accounting for 20% of global exports in terms of volume. Branded generics constituted nearly 70-80% of the domestic market. India’s long-term prospects appear promising; the Indian pharmaceutical industry is likely to emerge among the top 10 global markets by value by 2020 (Source: PwC-CII).

Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented.


    1. Aurobindo Pharma Ltd.
    2. Biocon
    3. Cipla Ltd.
    4. Dr Reddy’s Laboratories
    5. Glaxosmithkline Pharmaceuticals Ltd.
    6. Lupin Ltd.
    7. Novartis India Ltd.
    8. Pfizer Ltd.
    9. Ranbaxy Laboratories Ltd.
    10. Sun Pharmaceuticals Limited
    11. Torrent Pharmaceuticals Ltd.
    12. Wockhardt Ltd.


List of Tables for QTII-Pharmaceutical Industry

 Industry Analysis

  1. Industry Aggregate
  2. Industry cost structure as % of sales
  3. Industry related latest data

2. Inter – firm Comparison

  1. Turnover (Net Sales) of the Major Players
  2. Financial Performance
  3. Cost Structure (as percentage of sales) (for the quarter estimated)

3. Company Analysis

Twelve Tables for each 12 companies giving actual, estimated and forecasted data

 List of Graphs for QTII- Pharmaceutical Industry

 Industry Analysis

  1. Net Sales and Growth
  2. EBITDA and OPM
  3. PAT and NPM
  4. Cost structure as % of net sales
  5. Industry related latest data graph
  6. Inter-firm Comparison
    1. Sales Revenue and Growth (of 12 selected companies)
    2. Financial Performance (estimated current quarter compared to previous year same quarter)
    3. Comparison of Cost Structure across Companies (for the quarter estimated)

 Note: Quarterly Tracker of an industry will be prepared based on demand by a customer and delivery of the product will be done within a week’s time.


Sri Krishna Bharati Knowledge Services (SKBKS) specialises in analysis and research of Industries and Companies through long established and trusted methodologies. Solutions and services offered by us span the entire value chain of information, analysis and research. We cover market and business trends at global, regional and country levels. All products feature analytical content and are presented elegantly.

Our core line of business and services include Customized Research Projects, Content Writing, White Paper Preparation, Detailed Analysis as Industry Observer/Insights and Knowledge Partner for Associations. From macro-economic overview to closer insight into the smallest products /markets, we plan; design and co-ordinate data collection from primary and secondary sources and place the final analysis in context of your specific needs.

We support world’s leading consumer and industrial manufacturers, retailers, suppliers, business services, government departments, banks, consulting firms and trade promotion organisations, business schools and management colleges.

Our strength lies in keeping timelines, quality and integrity of its research and analysis. We believe in continuous innovation to keep our clients with knowledge updation in the industry. We value customer satisfaction.

Our Product and Services

  • Customized Research Projects
  • Content Writing
  • White Paper Preparation
  • Detailed Industry Analysis as Industry Observer/Insights
  • Knowledge partner for Associations

Our Periodicals Include

  • Global Industry Observer (GIO-monthly)
  • Quarterly Tracker-Indian Industries (QTII-Quarterly)
  • Half Yearly Industry Tracker (HYIT-Biannual)

Techno Economic Viability Studies (TEV Studies): We endeavor to take up TEV studies once empanelment by the banks is received. The company is in the process of obtaining empanelment.

For more information contact:

Sri Krishna Bharati Knowledge Services

House No.1-8-80, Temple Alwal,

Secunderabad 500010, Telengana

Tel: 040 – 27975666;

E-mail: skbks123@gmail.com